These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16472092)

  • 1. Topical DNA vaccination with DNA/Lipid based complex.
    Choi MJ; Kim JH; Maibach HI
    Curr Drug Deliv; 2006 Jan; 3(1):37-45. PubMed ID: 16472092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical vaccination of DNA antigens: topical delivery of DNA antigens.
    Choi MJ; Maibach HI
    Skin Pharmacol Appl Skin Physiol; 2003; 16(5):271-82. PubMed ID: 12907832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccine strategies: candidates for immune modulation and immunization regimens.
    Doria-Rose NA; Haigwood NL
    Methods; 2003 Nov; 31(3):207-16. PubMed ID: 14511953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic transfersomes based topical genetic vaccine against hepatitis B.
    Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
    Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced non-inflammasome mediated immune responses by mannosylated zwitterionic-based cationic liposomes for HIV DNA vaccines.
    Qiao C; Liu J; Yang J; Li Y; Weng J; Shao Y; Zhang X
    Biomaterials; 2016 Apr; 85():1-17. PubMed ID: 26851653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical immunization using nanoengineered genetic vaccines.
    Cui Z; Mumper RJ
    J Control Release; 2002 May; 81(1-2):173-84. PubMed ID: 11992690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic characterization of HIV-specific DNA vaccine.
    Ishii N; Sugita Y; Liu LJ; Watabe S; Toda S; Xin KQ; Okuda K
    J Investig Dermatol Symp Proc; 2001 Nov; 6(1):76-80. PubMed ID: 11764291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microparticles and nanoparticles as delivery systems for DNA vaccines.
    Cui Z; Mumper RJ
    Crit Rev Ther Drug Carrier Syst; 2003; 20(2-3):103-37. PubMed ID: 14584521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
    Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
    Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines.
    Weiss R; Scheiblhofer S; Freund J; Ferreira F; Livey I; Thalhamer J
    Vaccine; 2002 Aug; 20(25-26):3148-54. PubMed ID: 12163266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation.
    Vandermeulen G; Daugimont L; Richiardi H; Vanderhaeghen ML; Lecouturier N; Ucakar B; Préat V
    Pharm Res; 2009 Jul; 26(7):1745-51. PubMed ID: 19384465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.
    Vandermeulen G; Vanvarenberg K; De Beuckelaer A; De Koker S; Lambricht L; Uyttenhove C; Reschner A; Vanderplasschen A; Grooten J; Préat V
    Vaccine; 2015 Jun; 33(28):3179-85. PubMed ID: 25980430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
    Weniger BG; Anglin IE; Tong T; Pensiero M; Pullen JK;
    Vaccine; 2018 Jan; 36(4):427-437. PubMed ID: 29174315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
    Liu LJ; Watabe S; Yang J; Hamajima K; Ishii N; Hagiwara E; Onari K; Xin KQ; Okuda K
    Vaccine; 2001 Oct; 20(1-2):42-8. PubMed ID: 11567744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine.
    Kusakabe K; Xin KQ; Katoh H; Sumino K; Hagiwara E; Kawamoto S; Okuda K; Miyagi Y; Aoki I; Nishioka K; Klinman D; Okuda K
    J Immunol; 2000 Mar; 164(6):3102-11. PubMed ID: 10706700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response.
    Kwissa M; Lindblad EB; Schirmbeck R; Reimann J
    J Mol Med (Berl); 2003 Aug; 81(8):502-10. PubMed ID: 12879151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
    Calarota SA; Weiner DB
    Immunol Rev; 2004 Jun; 199():84-99. PubMed ID: 15233728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic and prophylactic DNA vaccines for HIV-1.
    Ramirez LA; Arango T; Boyer J
    Expert Opin Biol Ther; 2013 Apr; 13(4):563-73. PubMed ID: 23477730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines--challenges in delivery.
    Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
    Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.